Last reviewed · How we verify
NCT04689685: RADAR
The RADAR Study - Wearable-Based Dysglycemia Detection and Warning in Diabetes
trial testing Wearing smartwatch and continous glucose sensor in Diabetes Mellitus, Insulin-Dependent in 40 participants. Completed in 28 March 2022.
28 March 2022
Quick facts
| Lead sponsor | Insel Gruppe AG, University Hospital Bern |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 19 February 2021 |
| Primary completion | 28 March 2022 |
| Estimated completion | 28 March 2022 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Wearing smartwatch and continous glucose sensor
Conditions studied
- Diabetes Mellitus, Insulin-Dependent — all drugs for Diabetes Mellitus, Insulin-Dependent →
- Diabetes — all drugs for Diabetes →
Sponsor
Insel Gruppe AG, University Hospital Bern
Who can join
18 and older, any sex, with Diabetes Mellitus, Insulin-Dependent or Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study RADAR aims at developing a wearable based dysglycemia detection and warning system for patients with diabetes mellitus using artificial intelligence.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Noninvasive Hypoglycemia Detection in People With Diabetes Using Smartwatch Data.
Lehmann V, Föll S, Maritsch M, van Weenen E, et al · · 2023 · cited 22× · PMID 36805169 · DOI 10.2337/dc22-2290
Verify or expand the search:
- PubMed search for NCT04689685
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes Mellitus, Insulin-Dependent
Currently open trials in the same condition.
- NCT07011147 — Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery · NA · recruiting
Other Insel Gruppe AG, University Hospital Bern trials
Trials by the same sponsor.
- NCT06546384 — GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease · NA · not yet recruiting
- NCT07524049 — Giving Children a Voice in Paediatric Anaesthesia · not yet recruiting
- NCT07415668 — Motor Eloquent Navigated Transcranial Magnetic Stimulation for Radiosurgery Planning · NA · not yet recruiting
- NCT07478536 — Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial) · not yet recruiting
- NCT07201506 — Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04689685 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Insel Gruppe AG, University Hospital Bern
- Last refreshed: 14 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04689685.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing